KA
CRSP icon

Kovack Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Kovack Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$233K Buy
4,886
+310
+7% +$16.4K 0.01% 863
2025
Q4 		$240K Buy
+4,576
New +$274K 0.01% 861
2021
Q3 		– Sell
-1,434
Closed -$232K – 708
2021
Q2 		$232K Buy
+1,434
New +$174K 0.03% 592

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kovack Advisors's CRSP Position: Q1 2026 in Review

Kovack Advisors increased its CRISPR Therapeutics (CRSP) stake by 6.8% in Q1 2026, buying an estimated $16.4K and bringing the position to 4,886 shares worth $233K. The position accounts for 0.01% of the portfolio, ranked #863.

Kovack Advisors first reported a position in CRSP in Q2 2021 and has held it in 3 quarters since. The position peaked at $240K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Kovack Advisors held 4,886 shares of CRISPR Therapeutics worth $233K as of Q1 2026.
  • Kovack Advisors bought 310 CRISPR Therapeutics shares in Q1 2026, an estimated $16.4K.
  • CRISPR Therapeutics made up 0.01% of Kovack Advisors's portfolio in Q1 2026, its #863 holding.
  • Kovack Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Kovack Advisors's CRISPR Therapeutics position peaked at $240K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.